Lupin Limited
Search results
5 days ago · Biocon Biologics is transforming patient outcomes by making life-changing therapies more accessible to the world. Through affordable biosimilars, we are reducing the global healthcare burden, increasing treatment options and driving innovation in biologics, to advance health equity, globally.
5 days ago · Our novel biologics address unmet medical needs across the world. Research. saves lives. We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines. Stories of Hope: Joyeeta Chatterjee, a breast cancer survivor, who faced her challenges with courage and confidence.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide.
Biocon Biologics has invested over USD 1 billion to date in R&D and global scale manufacturing and has end-to-end capabilities for producing drug substance, drug product and delivery devices across multiple sites in India and Malaysia.
We have a broad pipeline of 20 biosimilar molecules spanning insulins, monoclonal antibodies and conjugated recombinant proteins, out of which eight are commercialized products.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Nov 10, 2024 · “The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ facilities at Biocon Park, Bengaluru, India, as Voluntary Action Indicated (VAI). “This relates to the combined cGMP inspection and Pre-Licensing Inspection (PLI) conducted by the agency between July 15 – 26, 2024.
Nov 11, 2024 · Biocon Biologics, its biosimilars arm, holds a portfolio of 20 biosimilars spanning across critical therapeutic areas such as oncology, immunology, and diabetes, with significant market share in advanced markets. The company also has a robust pipeline of over 20 molecules expected to be launched by 2030.
Nov 11, 2024 · Shares of Biocon today zoomed 5.4% to an intraday high of Rs 338.60 on the BSE after the company on Sunday after the U.S. Food and Drug Administration classified Biocon Biologics’ Bengaluru facility as Voluntary Action Indicated ().“The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ facilities at Biocon Park, Bengaluru, India, as Voluntary Action Indicated (VAI),” said the company in a statement in its filing to the stock exchanges.
Biocon Biologics is a leading global player in the development, manufacturing and commercialization of biosimilars. Our cutting-edge science, extensive portfolio of biosimilars, and commitment to quality and compliance make us a trusted choice for healthcare providers and patients worldwide.
